Investors Alerted: Class Action Lawsuit Against Applied Therapeutics
LOS ANGELES, Jan. 23, 2025 /PRNewswire/ — The Schall Law Firm, a national firm focusing on shareholder rights litigation, has announced a class action lawsuit against Applied Therapeutics, Inc. (“Applied Therapeutics” or “the Company”) APLT. This legal action stems from violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 issued by the U.S. Securities and Exchange Commission.
Investors who bought the Company’s securities from January 3, 2024 to December 2, 2024, are urged to reach out to Schall Law Firm before the deadline of February 18, 2025.
If you are an affected shareholder, click here to get involved.
You can also contact Brian Schall at Schall Law Firm, located at 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, by calling 310-301-3335, for a free discussion about your rights. Additional information can be accessed on the firm’s website at www.schallfirm.com, or via email at [email protected].
Note that the class action has not yet been certified. Until it achieves certification, individuals are not represented by an attorney. Those choosing not to act will remain absent class members.
The Complaint alleges that the Company issued false and misleading statements regarding its operations. Specifically, it claims that Applied Therapeutics did not follow the necessary trial protocols and good clinical practices for its drug candidate, govorestat. This negligence raised substantial concerns that the FDA might reject the Company’s trial data during the submission of the rovorestat New Drug Application (NDA). Thus, public statements made during this period were misleading, leading to investor losses once the truth was revealed.
Investors are encouraged to join the case to seek recovery for their losses.
The Schall Law Firm advocates for investors globally, concentrating on securities class action lawsuits and shareholder rights.
This press release may be categorized as Attorney Advertising in certain jurisdictions based on applicable rules and regulations.
CONTACT:
The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
View original content to download multimedia:https://www.prnewswire.com/news-releases/aplt-investors-have-opportunity-to-lead-applied-therapeutics-inc-securities-fraud-lawsuit-with-the-schall-law-firm-302358236.html
SOURCE The Schall Law Firm
Market News and Data brought to you by Benzinga APIs
